【目的】观察大黄牡丹汤对肠道菌群结构及功能的影响。【方法】分别采用16S r DNA测序法、平板计数法和气相色谱法考察大黄牡丹汤对肠道菌群及其分泌短链脂肪酸(short-chain fatty acids,SCFAs)功能的影响。【结果】16S r DNA测序结果...【目的】观察大黄牡丹汤对肠道菌群结构及功能的影响。【方法】分别采用16S r DNA测序法、平板计数法和气相色谱法考察大黄牡丹汤对肠道菌群及其分泌短链脂肪酸(short-chain fatty acids,SCFAs)功能的影响。【结果】16S r DNA测序结果表明拟杆菌属、埃希菌属细菌明显减少,乳杆菌属、乳球菌属、变形菌属细菌增多。平板计数结果表明大黄牡丹汤能显著抑制脆弱拟杆菌体外增殖(P<0.001)。气相色谱法检测结果表明大黄牡丹汤可显著抑制SCFAs的分泌(P<0.05或P<0.01或P<0.001)。【结论】肠道菌群及其代谢产物可能是大黄牡丹汤发挥药效的靶点。展开更多
目的通过研究结、直肠癌患者肠道拟杆菌属、梭杆菌属和梭菌属量的变化,揭示肠道相关菌群改变在大肠癌发病中的作用及意义。方法收集术前结、直肠癌患者粪便标本40例及正常对照标本40例,根据细菌的靶基因序列设计特异性引物。提取待测粪...目的通过研究结、直肠癌患者肠道拟杆菌属、梭杆菌属和梭菌属量的变化,揭示肠道相关菌群改变在大肠癌发病中的作用及意义。方法收集术前结、直肠癌患者粪便标本40例及正常对照标本40例,根据细菌的靶基因序列设计特异性引物。提取待测粪便标本细菌DNA,应用SYBR Green I实时荧光定量PCR测定不同细菌的数量。结果正常对照组与实验组粪便中细菌数量分别为拟杆菌属(8.76±0.77;9.85±0.88)、梭杆菌属(7.94±1.25;10.0±1.65)、梭菌属(3.54±0.70;6.56±0.68),拟杆菌属中的脆弱拟杆菌为(2.12±0.48;4.07±1.77)、梭杆菌属中的坏死梭杆菌为(2.31±0.26;7.62±2.68)及梭菌属中的肉毒梭菌为(2.76±1.16;5.43±1.21),实验组数量均明显增多(P<0.05)。结论结、直肠癌患者粪便中拟杆菌属、梭杆菌属和梭菌属的数量较正常对照明显增多,提示结、直肠癌的发生发展与肠道菌群有明显关系。展开更多
Objective To investigate whether astragalus polysaccharides(APS)combined with berberine(BBR)can reduce high-fat diet(HFD)-induced obesity in mice.Methods Except for normal mice,32 HFD-induced obese mice were randomize...Objective To investigate whether astragalus polysaccharides(APS)combined with berberine(BBR)can reduce high-fat diet(HFD)-induced obesity in mice.Methods Except for normal mice,32 HFD-induced obese mice were randomized into HFD,APS(1,000 mg/kg APS),BBR(200 mg/kg BBR),and APS plus BBR(1,000 mg/kg APS plus 200 mg/kg BBR)groups,respectively.After 6-week treatment(once daily by gavage),the obesity phenotype and pharmacodynamic effects were evaluated by histopathological examination of epididymal fat,liver,and colon using hematoxylin-eosin staining and serum biochemical analyses by an automated chemistry analyzer.The feces were collected at the 12 th week,and taxonomic and functional profiles of gut microbiota were analyzed by 16S ribosomal ribonucleic acid(16S rRNA)sequencing.Results Compared with HFD group,the average body weight of APS plus BBR group was decreased(P<0.01),accompanied with the reduced fat accumulation,enhanced colonic integrity,insulin sensitivity and glucose homeostasis(P<0.05 or P<0.01).Importantly,APS combined with BBR treatment was more effective than APS or BBR alone in improving HFD-induced insulin resistance(P<0.05 or P<0.01).16S rRNA sequence-based analysis of fecal samples demonstrated that APS combined with BBR treatment exhibited a better impact on HFD-induced gut microbiota dysbiosis,exclusively via the enriched abundances of Bacteroides,which corresponded to the large increase of predicted bacterial genes involved in carbohydrate metabolism.Conclusion APS combined with BBR may synergistically reduce obesity and modulate the gut microbiota in HFD-fed mice.展开更多
文摘【目的】观察大黄牡丹汤对肠道菌群结构及功能的影响。【方法】分别采用16S r DNA测序法、平板计数法和气相色谱法考察大黄牡丹汤对肠道菌群及其分泌短链脂肪酸(short-chain fatty acids,SCFAs)功能的影响。【结果】16S r DNA测序结果表明拟杆菌属、埃希菌属细菌明显减少,乳杆菌属、乳球菌属、变形菌属细菌增多。平板计数结果表明大黄牡丹汤能显著抑制脆弱拟杆菌体外增殖(P<0.001)。气相色谱法检测结果表明大黄牡丹汤可显著抑制SCFAs的分泌(P<0.05或P<0.01或P<0.001)。【结论】肠道菌群及其代谢产物可能是大黄牡丹汤发挥药效的靶点。
文摘目的通过研究结、直肠癌患者肠道拟杆菌属、梭杆菌属和梭菌属量的变化,揭示肠道相关菌群改变在大肠癌发病中的作用及意义。方法收集术前结、直肠癌患者粪便标本40例及正常对照标本40例,根据细菌的靶基因序列设计特异性引物。提取待测粪便标本细菌DNA,应用SYBR Green I实时荧光定量PCR测定不同细菌的数量。结果正常对照组与实验组粪便中细菌数量分别为拟杆菌属(8.76±0.77;9.85±0.88)、梭杆菌属(7.94±1.25;10.0±1.65)、梭菌属(3.54±0.70;6.56±0.68),拟杆菌属中的脆弱拟杆菌为(2.12±0.48;4.07±1.77)、梭杆菌属中的坏死梭杆菌为(2.31±0.26;7.62±2.68)及梭菌属中的肉毒梭菌为(2.76±1.16;5.43±1.21),实验组数量均明显增多(P<0.05)。结论结、直肠癌患者粪便中拟杆菌属、梭杆菌属和梭菌属的数量较正常对照明显增多,提示结、直肠癌的发生发展与肠道菌群有明显关系。
基金Supported by the National Natural Science Foundation of China(Nos.82130112,81903786,81773891)Shaanxi Administration of Traditional Chinese Medicine(No.2019-ZZ-JC018)+1 种基金the National Great New Drugs Development Project of China(No.2017ZX09301-040)the Natural Science Foundation of Shaanxi Province(No.2019JQ-054)。
文摘Objective To investigate whether astragalus polysaccharides(APS)combined with berberine(BBR)can reduce high-fat diet(HFD)-induced obesity in mice.Methods Except for normal mice,32 HFD-induced obese mice were randomized into HFD,APS(1,000 mg/kg APS),BBR(200 mg/kg BBR),and APS plus BBR(1,000 mg/kg APS plus 200 mg/kg BBR)groups,respectively.After 6-week treatment(once daily by gavage),the obesity phenotype and pharmacodynamic effects were evaluated by histopathological examination of epididymal fat,liver,and colon using hematoxylin-eosin staining and serum biochemical analyses by an automated chemistry analyzer.The feces were collected at the 12 th week,and taxonomic and functional profiles of gut microbiota were analyzed by 16S ribosomal ribonucleic acid(16S rRNA)sequencing.Results Compared with HFD group,the average body weight of APS plus BBR group was decreased(P<0.01),accompanied with the reduced fat accumulation,enhanced colonic integrity,insulin sensitivity and glucose homeostasis(P<0.05 or P<0.01).Importantly,APS combined with BBR treatment was more effective than APS or BBR alone in improving HFD-induced insulin resistance(P<0.05 or P<0.01).16S rRNA sequence-based analysis of fecal samples demonstrated that APS combined with BBR treatment exhibited a better impact on HFD-induced gut microbiota dysbiosis,exclusively via the enriched abundances of Bacteroides,which corresponded to the large increase of predicted bacterial genes involved in carbohydrate metabolism.Conclusion APS combined with BBR may synergistically reduce obesity and modulate the gut microbiota in HFD-fed mice.
